Catalent Softgel Expert to Present on Bioavailability Improvement at the 3rd Annual Drug Repositioning & R&D Enhancement Conference
Somerset, NJ, September 9, 2010 -- Jeffrey E. Browne, Ph.D. Technical Director, Pharmaceutical Softgel Business Development, Catalent Pharma Solutions, will be presenting at the 3rd Annual Drug Repositioning & R&D Enhancement Conference, September 14-15, 2010, in Philadelphia, PA. Dr. Browne’s presentation, “Repositioning Drug Products in Conventional Dosage Forms to Softgel Technology for Improved Bioavailability & Patient Compliance” will take place on Wednesday, September 15, 2010 at 11:30 AM. In addition, Dr. Browne will also participate in the panel discussion “Evaluating the Role of Technology in Repositioning Products”, September 15 at 3:15 PM.
The presentation will focus on the usage of softgel dosage form technology to reposition drug products. Dr. Browne will discuss how immediate and modified release softgels can be used to enhance the bioavailability of poorly water soluble and low membrane permeability drugs. Additionally, the presentation will include discussion on the use of softgel technology for repositioning drug products based on improving their drug product quality and patient compliance.
Throughout his career, Dr. Browne has held various positions in pharmaceutical manufacturing & technical services, as well as drug delivery R&D, with a focus on topical, transdermal, inhalation, and oral liquid dosage forms. In 1994, Dr. Browne joined Catalent Pharma Solutions (formally RP Scherer and Cardinal Health Pharmaceutical Technologies & Services) and has expanded his expertise in a variety of positions including: VP Softgel R&D in St. Petersburg, FL; Executive Director & Division Head of Pharmaceutical Development in RTP, NC; Director of Technical Services in St. Petersburg, FL; Account Director, Business Development; and most recently, Technical Director, Pharmaceutical Softgels. Dr. Browne holds his Ph.D. in Industrial & Physical Pharmacy from Purdue University. He is active in the American Association of Pharmaceutical Scientists (AAPS), serving on several Focus Group committees and has presented frequently at regional and national AAPS meetings. He also serves on the Industrial Advisory Board of the Dane O. Kildsig Center for Pharmaceutical Processing Research, a center which encourages cooperative research between academia and industry.
For more information or to register for the conference, visit www.marcusevans.com .
To learn more about Catalent’s softgel technologies, go to www.catalent.com/offerings . To contact Dr. Jeffrey Browne with specific softgel technology inquiries or to arrange a consultation with Dr. Browne and the softgel team at the upcoming 3rd Annual Drug Repositioning & R&D Enhancement Conference, please contact, Jeff.Browne@catalent.com.
Headquartered in Somerset, New Jersey, Catalent Pharma Solutions is a leading provider of advanced dose form and packaging technologies, and development, manufacturing and packaging services for pharmaceutical, biotechnology and consumer healthcare companies in nearly 100 countries. Catalent applies its local market expertise and technical creativity to advance treatments, change markets and enhance patient outcomes. Catalent employs approximately 9,000 people at 30 facilities worldwide and in fiscal 2009 generated more than $1.6 billion in annual revenue. For more information, visit www.catalent.com .